Clinical Trial

Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 8, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The incidence of acute kidney injury (AKI) after radical nephrectomy exceeds 40%. Currently, the KDIGO criteria are the recognized diagnostic standard for AKI. These criteria primarily use serum creatinine and urine output as key indicators, but both parameters have certain limitations, such as delayed response, insensitivity, and inaccuracy. This study aims to simultaneously monitor perioperative novel renal damaging, stressful, and functional biomarkers in patients undergoing radical nephrectomy, and to investigate their predictive value for AKI and postoperative 1-year chronic kidney disease (CKD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2025-08-31
Trial Details
NCT Number NCT07088874
Lead Sponsor Peking University First Hospital
Conditions Nephrectomy, Acute Kidney Injury, Biomarker
Enrollment 60 participants
Start Date 2025-08-02
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-08